# Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

> **NCT07333274** · PHASE3 · RECRUITING · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 335 (estimated)

## Conditions studied

- Head & Neck Squamous Cell Carcinoma
- Head & Neck Cancer

## Interventions

- **DRUG:** Nimotuzumab
- **RADIATION:** intensity-modulated technique（IMRT）

## Key facts

- **NCT ID:** NCT07333274
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-05
- **Primary completion:** 2028-01-05
- **Final completion:** 2030-01-05
- **Target enrollment:** 335 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07333274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07333274, "Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07333274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*